S-488210 is a Subunit Vaccine owned by Shionogi &, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.

S-4884210 is a peptide vaccine. Upon administration of peptide vaccine, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.

The revenue for S-488210 is expected to reach a total of $154m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the S-488210 NPV Report.

S-488210 was originated by OncoTherapy Science and is currently owned by Shionogi &.

S-488210 Overview

S-488210 is under development for the treatment of non-muscle invasive bladder cancer, recurrent and/or metastatic head and neck squamous cell carcinoma after failure of platinum based chemotherapy. It is administered through subcutaneous injection as powder for injection. S-488210 is a cancer peptide vaccine, which contains the three human leukocyte antigens (HLA) -restricted peptides up-regulated lung cancer 10, cell division cycle-associated protein 1 and insulin-like growth factor 2 mRNA-binding protein 3. It was also under development for the treatment of oral cancer, oropharyngeal cancer, laryngeal cancer and hypopharyngeal cancer 

Shionogi & Overview

Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.

Quick View – S-488210

Report Segments
  • Innovator
Drug Name
  • S-488210
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.